{"name":"AN2 Therapeutics","slug":"an2","ticker":"ANTX","exchange":"NASDAQ","domain":"an2therapeutics.com","description":"AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies. The company's lead product, ANX-030, is a novel antibiotic targeting multi-drug resistant bacteria. AN2 Therapeutics is positioned to address the growing need for effective treatments against antibiotic-resistant infections.","hq":"Menlo Park, CA","founded":0,"employees":"","ceo":"Hala Mirza","sector":"Anti-Infectives Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$680M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":24769000,"netIncome":-35174000,"cash":19941000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"ANX-030 patent cliff ($0.0B at risk)","drug":"ANX-030","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AN2-502998","genericName":"AN2-502998","slug":"an2-502998","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AN2-502998","genericName":"AN2-502998","slug":"an2-502998","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"AN2 Therapeutics Announces FDA Fast Track Designation for ANX-030","summary":"AN2 Therapeutics announced that the FDA has granted Fast Track designation to ANX-030 for the treatment of complicated urinary tract infections (cUTIs) caused by multi-drug resistant bacteria.","drugName":"ANX-030","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"AN2 Therapeutics Reports Third Quarter 2023 Financial Results","summary":"AN2 Therapeutics reported its third quarter 2023 financial results, with a net loss of $13.4 million and cash and cash equivalents of $143.1 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-17","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOS1NOUUt1QmlmSk1RMTlRMks3YzJlZ21hVlk3d2xhdElIaFFoWXk1MVZEZFV3QnFPaTJ4N2p6R2FJQ29XUy13bF9jZmpWYlM2VWk1OHZrT0g5T2VLaG8ycHk3WTVQZF8ycG13Z1p6Q082Y2tXVEdYSGNQWUxHeTZNeVBCdVQ2RFBTQ2ZiLUZmc3JYYjlmbUR5ZlFDdlJOemJqbWRfTVY4VHFPbTRnQVhwSTZn?oc=5","date":"2026-03-09","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Monday's Intraday Session - Acurx Pharmaceuticals (NASDAQ:ACXP), Firefly - Benzinga","headline":"12 Health Care Stocks Moving In Monday's Intraday Session - Acurx Pharmaceuticals (NASDAQ:ACXP), Firefly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOc3UxZFZIVHpFeFU4OW9ILUVNdnVDaWc2UnBWdU11SGRiSVhiTk84ZzFzREpRbVNqQWJLbmRYTGFfR3JNckx5ZkVFNDNiMHFpOGdIREprWEp0NGxobWlvT3lZUjVmUFFydVVYT2tKYWlTMHc3b1Vxdzdtd3lXSndsMFdUbXpld2hCMkVhekxxWVNVWnhIRDBzbFNQLUtKU0NHQ0tWa0pjVm5aeXZiYzFRQVpNcXFHNDJ2WHBhamFmWFBTYVU?oc=5","date":"2026-03-09","type":"pipeline","source":"Business Wire","summary":"AN2 Therapeutics Announces $40 Million Private Placement Financing - Business Wire","headline":"AN2 Therapeutics Announces $40 Million Private Placement Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPNDJmSENZbDV4c3hYWnF3Z252QlZFMG1hVlNBQjA2UjA3cTlUWkhfWjdXaUJid05Ydlh6Y3dHWEttRkkwQ2Z4VW1qX0hJWkFzY1VnUGhDaGZWVVhRME41aU55NlVmUm5RSVpmYnd4Sl9nd1JNaFAxQ09kcFo5cHh6ZGRnY0ZMU2Ryd09zcHZiOWdmTUM4SmttOEtBOW5mX0JBMEM2UlJFSGhHb0VDZEpEcDhR?oc=5","date":"2026-03-06","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Friday's Intraday Session - Firefly Neuroscience (NASDAQ:AIFF), AN2 Thera - Benzinga","headline":"12 Health Care Stocks Moving In Friday's Intraday Session - Firefly Neuroscience (NASDAQ:AIFF), AN2 Thera","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-28","type":"pipeline","source":"simplywall.st","summary":"AN2 Therapeutics Gains 11%, Insider Trades Reap Benefit - simplywall.st","headline":"AN2 Therapeutics Gains 11%, Insider Trades Reap Benefit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNamplZmtYaVRRczBiVTVWTTlwMktEVHE2bWZ5bGw2MllHeUY5X2xGOEVqdGtuQ3V5REJzanVOdlhCeG9tWkh6OGZGUzBTbU0xZ3VEam5rbEFwSi1LRUE2T1Y1VWlfbE0xLVpVTUh4ZnBSZjZWTE55NUo3ZmEtLUFLNkpqbmVuZHU0MGt5c3VzeXk5NjZoSGRGTnFoQ3ZtcGxIckdPUzJRZ3pkQ1BEaGVrMWIyT3B5WGx1bGRyWkh3aWw1Z2xSRUw5cHphdlFNU0xCS3Z6MUEteUJzS0lHU25JVHM5STjSAeoBQVVfeXFMTnJtQXJDcUVLbnhMQmpNaThrSWtMZkdIZWRsbWU4a2RLb2RZMkRtUjRmU3cwMmFIZG00Y1NUcjNlMVRWQ3MwdXVIemNIZUhBSGZvUE15SVhUeWg2NlI5VUU1UkFLZncxY2tlTE1NWkl6YWhtazdXMElVSkFfTU9kNGRmTVFEdVZVbGFJVnZCSUZ1OEJBaURQRmdnUkk3TW5kSGtQazd0MmVpemRrMHpwdHg5NFc5WlVDZXVsU0ZEdmtQTXU5Q19rV25Kb0tNNGVHemhrbW1XTUROcnc4R2h3dDBYaGx2MEFLdm5R?oc=5","date":"2025-09-04","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation - simplywall.st","headline":"Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1WSHRTRHE3LVRlVzJ0UjJCY3pYYnh1TjZNbmFlVnpuc2R5ZFFjWUQwX1ptc2QxeW5KbDZPdnVQLTJtZk5sck9MZG01NFRfeFZXVkhB?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"ANTX Stock Price, News & Analysis - Stock Titan","headline":"ANTX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBEZlB5TkVuUXlNZ1dCN09JYkU0WENfNFVMSDU3dlBMekRqZ29hMkdxOTRkcE1NVWYxLWQ3aGNMRGlfQXNmTTZwVElzZHhQRWhqaXJn?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"CASI Stock Price, News & Analysis | Casi Pharmaceuticals - Stock Titan","headline":"CASI Stock Price, News & Analysis | Casi Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE04Y2x2SlpnbnVjZWl1YW02U2N4b09zYlF6Q2xGUWRJblNvR1FvNzNyUE1MQk13alpSbi02SGxVTkVZMk13aFdRempob0I1aVBIdDhNMWQ5Q0lQU0lk?oc=5","date":"2024-04-28","type":"pipeline","source":"TradingView","summary":"ANTX Stock Price and Chart — NASDAQ:ANTX - TradingView","headline":"ANTX Stock Price and Chart — NASDAQ:ANTX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBTSUdYbjlWWDQzWHlSa3BFck91QlNfUFhlRVpzMFdzNWJpSTNKX2xVdTVaWnZnTGlocUNidXV4LUlIcHNVXzVuZldPTGdtc0FEMVE?oc=5","date":"2017-05-23","type":"pipeline","source":"Yahoo Finance UK","summary":"AN2 Therapeutics, Inc. (ANTX) stock price, news, quote and history - Yahoo Finance UK","headline":"AN2 Therapeutics, Inc. (ANTX) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"ANX-030","drugSlug":"novel-antibiotic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merck & Co.","Pfizer Inc.","Gilead Sciences Inc."],"therapeuticFocus":["Anti-Infectives"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":24769000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-35174000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":19941000,"cashHistory":[],"totalAssets":61950000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}